Skip to main content
. Author manuscript; available in PMC: 2021 Oct 1.
Published in final edited form as: Psychiatry Res. 2020 Jul 2;292:113269. doi: 10.1016/j.psychres.2020.113269

Table 2.

Results of multiple linear regressions examining the interaction of methamphetamine (METH) status and COMT genotype on dopamine (DA), homovanillic acid (HVA) and HVA/DA ratios

Outcome: CSF DA (log) beta (SE) 95% CI p
METH+ (vs. METH−)a −1.10 (0.55) −2.20, 0.00 0.050
Val/Met (vs. Met/Met)b −0.89 (0.51) −1.90, 0.12 0.082
Val/Val (vs. Met/Met)b −1.18 (0.58) −2.34, −0.02 0.046
METH+ x Val /Met 1.56 (0.67) 0.24, 2.89 0.021
METH+ x Val/ Val 1.09 (0.76) −0.42, 2.59 0.154
Outcome: CSF HVA (log) beta (SE) 95% CI p
METH+ (vs. METH−)a 0.13 (0.47) −0.81, 1.07 0.778
Val/Met (vs. Met/Met)b −0.46 (0.44) −1.33, 0.40 0.291
Val/Val (vs. Met/Met)b −0.35 (0.50) −1.34, 0.64 0.482
METH+ x Val /Met −0.06 (0.57) −1.19, 1.08 0.918
METH+ x Val/ Val −0.59 (0.65) −1.88, 0.70 0.366
Outcome: CSF HVA/DA (log) beta (SE) 95% CI p
METH+ (vs. METH−)a 1.24 (0.54) 0.16, 2.32 0.025
Val/Met (vs. Met/Met)b 0.43 (0.50) −0.56, 1.42 0.391
Val/Val (vs. Met/Met)b 0.83 (0.57) −0.31, 1.97 0.152
METH+ x Val /Met −1.62 (0.66) −2.93, −0.32 0.015
METH+ x Val/ Val −1.68 (0.75) −3.15, −0.20 0.026
a

Represents effect of METH in Met/Met individuals only (reference group)

b

Represents effect of COMT in METH- individuals only (reference group)